Shared Care & Integrated Medicines Optimisation Committee (IMOC)



UPDATE FOR SHEFFIELD GPS

September 2024

IMOC has recently approved Liothyronine despite objections expressed by General Practice representatives in South Yorkshire. It is very disappointing that General Practice's concerns are not taken into account, and decisions are being made about us without our consent.

Sheffield LMC, as well as Barnsley and Rotherham LMCs, has withdrawn from the process, as there is no value in attending meetings where the voice of General Practice is not heard and our concerns ignored.

It is important to note that just because IMOC has approved a drug for shared care, it does not mean that General Practice in Sheffield will automatically sign up to it. Shared care is voluntary, and it is for your individual practice to decide if you want to engage with it or not. Unresourced and inappropriate work being shifted into General Practice can be dangerous, as it puts undue pressure on General Practice to deliver services without the appropriate support, and that does not improve care for your patients. There is a real danger that practices will be pushed to deliver more and more unresourced shared care. Therefore, we advice practices to consider if this is appropriate for your patient care and for the sustainability of your practice. If you do not feel it is, you should inform the appropriate secondary care colleagues and either withdraw from existing shared care arrangements and/or not sign up to any new shared care protocols.

We are continuing to engage with commissioners outside of IMOC to secure appropriate funding for shared care.

DR KRISHNA KASARANENI Executive Officer

DR ALASTAIR BRADLEY Chair